Static export generated 2026-07-28 07:45Z from the private Meridian research build — every value keeps its own as-of timestamp and provenance label; search, filters and admin actions are inactive in this copy. Private academic review only — not for redistribution.
MERIDIAN Regulatory & Corporate Impact Intelligence — personal research build
Data coverage is not complete: 3 source(s) failing; 24 open coverage incident(s); 1 source(s) awaiting credentials; 3 source(s) unverified. Details on the Source Health page — gaps are shown, never concealed.

Kühne + Nagel International AG

Identity (GLEIF Global LEI Index)

FieldValueClass
Legal nameKühne + Nagel International AGSF
LEI529900Q0YED3805QXQ66SF
Swiss UIDCHE101862298SF
JurisdictionCHSF
Legal addressDorfstrasse 50, 8834, SchindellegiSF
HeadquartersDorfstrasse 50, 8834, Schindellegi Schindellegi CH-SZSF
Entity statusACTIVESF
Geneva connectionnoneCM

Listed securities (SIX Swiss Exchange issuer directory)

ISINTickerMICShare classSegmentAccounting standardNext GMAuditorProv.
CH0025238863KNINXSWXRegistered ShareInternational Reporting StandardIFRS2027-05-05KPMG AG - CH[501403]

Market snapshot

210.30 CHF
Stale — 11 days old · delayed per exchange agreement · yahoo

MetricValueClass
SMA 20201.43CM
SMA 50189.78CM
52-week range position100% of range 148.15–210.60CM
Trend (SMA20 vs SMA50)upCM
History depth261 daily barsSF

Analyst price targets

LowMeanMedianHighAnalystsProviderAs of
154.0187.77779187.0230.018yahoo_analyst2026-07-18T22:46:46Z

Consensus recommendation (provider-published): hold

Financials (latest reported period)

Most recent reported income-statement figures (company disclosure redistributed by the named source); absent figures stay absent — never estimated.

Period ending 2025-12-31 (annual) · reported in CHF

MetricValueClass
Revenue24.5B CHFSF
Gross profit8.8B CHFSF
Operating income1.2B CHFSF
EBITDA2.2B CHFSF
Net income882.0M CHFSF
EPS7.42SF
2 further data fields this platform tracks — no connected source covers this issuer yet. Shown to demonstrate capacity; each populates automatically when a source does, and nothing is estimated in the meantime. Show what is tracked ›

Recent company events

News, insider transactions, congressional trading disclosures and analyst-estimate snapshots from connected sources, each with provenance. Analyst estimates are forecasts — never price targets.

No company events ingested yet — the FMP rotation families (news, insider transactions, congressional disclosures, analyst estimates) populate this once a key is configured. Nothing is invented in the meantime.

Segment & geographic revenue (company disclosures)

Figures parsed from filings and redistributed by the named provider; values are shown as reported and shares are Calculated Metrics with the formula in the column header.

No disclosed segment or geographic revenue ingested for this company yet. The Business Quant pipeline (SEC-parsed company disclosures) reaches US-listed issuers progressively within its daily budget; issuers that do not disclose segment detail keep this honest state.

How the company makes money

Business description and sector are sourced facts (Yahoo assetProfile / Wikidata / Wikipedia — source named per value); the registry-disclosed purpose follows. Disclosed segment/geographic revenue appears in the card above when the issuer reports it; official EDGAR-XBRL and ESEF facts feed the financials card since 2026-07-07. Nothing is estimated in the meantime.

Kuehne + Nagel International AG is a global transport and logistics company based in Schindellegi, Switzerland. Its main owner and operator is Klaus-Michael Kühne via his Kühne Holding and Kühne Foundation. The company was founded in 1890 in Bremen, Germany. It provides sea freight and airfreight forwarding, contract logistics, and overland businesses. As of 2023, it has nearly 1,300 offices in over 100 countries and nearly 79,000 employees. SF
source: wikipedia · retrieved 2026-07-19

Sector: freight transport, logistics, transport peers

Registry-disclosed purpose: Access currently requires credentials — the Swiss registry (Zefix) API returned HTTP 401 anonymously (verified 2026-07-02); registered-purpose text will populate once free Zefix credentials are configured in .env.

Corporate registry (OpenCorporates)

Official company-registry data aggregated by OpenCorporates; each value carries the registry's own snapshot date. Officers appear only where the registry publishes them (Swiss registries do not). The presence sweep lists same-name registrations across jurisdictions as labelled inference — never asserted subsidiaries.

Status: ACTIVE · Legal form: MVII · Registered address: Dorfstrasse 50, 8834, Schindellegi · OC jurisdiction: CH · registry record ↗ · registry snapshot as of 2021-01-14

Registry presence sweep (1 candidate entities, Evidence-Based Inference — match basis recorded per row): ch (1)

Regulators of highest concern

Ranked by maximum applicability of evidence-backed matches; when none exist yet, the jurisdictional supervision context derived from listing venue/domicile is shown instead — labelled, never asserted as a match.

AuthorityJur.MatchesMax applicabilityMax confidence
EU Publications Office (EU law)EU100.650.78
us_congressUS60.650.68
General Services AdministrationUS10.650.68

Regulatory exposure — matches with evidence

The price-impact column is a LABELLED INFERENCE (EBI): reasoning about whether and why the exposure could bear on the share price, derived from the regulation's type, region and topic and the match layer/direction. It is not an asserted fact and states no magnitude; the Applicability/Confidence/Exposure figures and the linked evidence remain the sourced basis.

RuleInstrumentRelationshipApplicabilityConfidenceExposurePotential price impact (inference)Review
R-SECTOR-TARIFFS_TRADE_REMEDIESGeneral Services Acquisition Regulation; Acquisition of Information and Communication Techsector_topic_candidate_tariffs_trade_remedies0.650.68Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1022R(01): Corrigendum to Commission Delegated Regulation (EU) 2026/1022 of 30sector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1022: Commission Delegated Regulation (EU) 2026/1022 of 30 April 2026 amendingsector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1457: Commission Implementing Regulation (EU) 2026/1457 of 29 June 2026 on thesector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1461: Regulation (EU) 2026/1461 of the European Parliament and of the Council sector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1455: Regulation (EU) 2026/1455 of the European Parliament and of the Council sector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1463: Council Regulation (EU) 2026/1463 of 25 June 2026 amending Regulation (Esector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1465: Council Regulation (EU) 2026/1465 of 25 June 2026 amending Regulation (Esector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1422: Commission Implementing Regulation (EU) 2026/1422 of 25 June 2026 amendisector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026R1540: Commission Implementing Regulation (EU) 2026/1540 of 6 July 2026 imposinsector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESHR 9601 (119th Congress): To direct the United States Trade Representative to initiate invsector_topic_candidate_tariffs_trade_remedies0.650.68Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESS 4883 (119th Congress): A bill to amend the Export Control Reform Act of 2018 to increasesector_topic_candidate_tariffs_trade_remedies0.650.68Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESS 4840 (119th Congress): Export Control Enforcement and Enhancement Actsector_topic_candidate_tariffs_trade_remedies0.650.68Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESHR 8169 (119th Congress): Export Control Enforcement and Enhancement Actsector_topic_candidate_tariffs_trade_remedies0.650.68Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESHR 4326 (119th Congress): To require the Congressional Budget Office to conduct an economisector_topic_candidate_tariffs_trade_remedies0.650.68Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESHR 8770 (119th Congress): SAFEGUARDS Act of 2026sector_topic_candidate_tariffs_trade_remedies0.650.68Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review
R-SECTOR-TARIFFS_TRADE_REMEDIESCELEX:32026D1760: Political and Security Committee Decision (CFSP) 2026/1760 of 14 July 20sector_topic_candidate_tariffs_trade_remedies0.650.78Insufficient evidence to calculateEBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed.
Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.
needs_review

Recent filings — potential impact inputs

A filing flags potential impact only via evidence-backed matching between its disclosed content and tracked measures.

No filings ingested yet. The authoritative filing venue for this issuer is SIX Exchange Regulation — issuer ad-hoc disclosures via SIX Swiss Exchange; an ingestion adapter for that venue is a tracked phased expansion. The gap stays visible — never padded.